Bereskin & Parr LLP
Subscribe Twitter Linked-in RSS

News & Publications

FIND AN ARTICLE

SUBSCRIBE TODAY

Keep informed about the latest news
and updates from Bereskin & Parr



 

Lindsey Robinson

MEDIA CONTACT
Lindsey Robinson
B.A. (Hons.), LLM
Manager, Business Development & Marketing
416.957.1663

 

 Bookmark this page  Print this page

European Regulators Update Guideline on Protein Biosimilars

February 17, 2015

Author: Noel Courage

The European Medicines Agency (“EMEA”) has provided updated guidance on obtaining protein biosimilar approvals. This document is called “Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues” (EMEA/CHMP/BMWP/42832/2005 Rev1).  This follows circulation of a draft to industry for comment in 2013. The new guideline is effective July 1, 2015.

The document provides the non-clinical and clinical requirements for a biosimilar to be approved for marketing in Europe. The guidance is significant because other regulators often look to the EMEA criteria - Europe is a leader in developing criteria for biosimilar approvals. The revised guidance emphasizes conducting non-clinical and clinical studies in a stepwise manner and outlines recommended approaches. 

The non-clinical requirements include analytical studies and pharmaco-toxicological studies. Analytical studies, such as assessing target binding and functional effects, should be comparative, showing similarity to the reference (brand name) drug.  The assays and data required will depend on the product class. The studies must show that in vitro assays are representative/predictive of clinical effects. 

The clinical section addresses the requirements for pharmacokinetic, pharmacodynamic, and efficacy studies. It also addresses clinical safety. The clinical portion of the revision addresses, for example, study design, choice of patient population and endpoints in efficacy trials. Safety is also addressed, including risk management, pharmacovigilance and immunogenicity study design (the EMEA has a separate guidance document on immunogenicity studies). 

Providing data to support extrapolation of safety and efficacy is also addressed, which is a particular point of interest.  The approved reference product may have multiple therapeutic indications.  Biosimilar companies typically want to demonstrate biosimilarity in one indication and extrapolate the clinical data to other indications.  For example, in September 2013, the EMEA approved Europe’s first biosimilar antibody. The drug was Inflectra which is a biosimilar of Remicade (infliximab), an anti-TNF-α antibody to treat autoimmune diseases. Remicade sales in Europe were over US$2 billion in 2012. The EMEA was willing to fully extrapolate from the limited clinical data set in the Inflectra drug submission to all the other approved previously approved indications for the reference product. As a result, Inflectra was approved in Europe for the treatment of inflammatory conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis. The situation was different in Canada, where the regulator, Health Canada, did not permit extrapolation to Crohn's disease and ulcerative colitis. The type of guidance provided by the EMEA will assist biosimilar manufacturers to obtain approval and extrapolate indications, but it is up to manufacturers to make sure they have a suitably strong data set to take internationally when seeking approval.

This article was originally published on AIPLA's Biotech Buzz, February 2015 newsletter.

Information on this website is for information only. It is not, and should not be taken as, legal advice. You should not rely on, or take or not take any action, based upon this information. Professional legal advice should be promptly obtained. Bereskin & Parr LLP professionals will be pleased to advise you.

 

About Us

Overview
People Clients Diversity and Inclusion

Accolades
Archives

Offices

Hours of Operation

Our People

All

Refine search by
Type Office Practice School

Services

Patents
Automotive Chemical Cleantech Electrical & Computer Technology Life Sciences Mechanical & Industrial Processes Medical Devices Nanotechnology Oil & Gas Plant Breeders’ Rights in Canada

Industrial Designs

Trademarks

Litigation

Financial Technology

IP Management & Strategic Counselling

Licensing & Transactions

Regulatory, Advertising & Marketing

Copyright & Digital Media

News & Publications

Newsroom
Archive

Articles
Article Archives

Newsletters

Media & Press

Litigation Cases
Patent Trademark Copyright

Subscribe

Webinars

Students

Overview

Articling Program

Summer Program

Recruitment
Articling Recruitment Second Year Recruitment First Year Recruitment Career Fairs

B&P Your University

Current Students

University Prizes

How to Apply

Events

Events Calendar

Student Events Calendar

Offices

Careers

Support Staff

Professionals

Students

Languages

English

Français

中国语

日本語

Search